Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anebulo Pharmaceuticals Inc (NQ: ANEB )

1.980 -0.060 (-2.95%)
Streaming Delayed Price Updated: 11:48 AM EDT, Aug 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Anebulo Pharmaceuticals Inc

< Previous 1 2 3 Next >
Anebulo is Developing an Antidote to Cannabis Intoxication
The company Anebulo Pharmaceuticals (NASDAQ: ANEB) is investing in an antidote for cannabis intoxication. The social and medical issues associated with acute cannabis intoxication... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Treatment of Cannabis Toxicity
The increasing prevalence and potency of cannabis following the legalization of recreational marijuana sales in a number of states have also increa... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Ascendis Pharma (NASDAQ:ASND) st... 
Via Benzinga
Cannabis Legalization is Driving an Increase in Related ER Visits
The legalization of both medical use and recreational use of cannabis in the United States has lead to an increase in both availability and potency... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Alcohol, Cannabis and Synergistic Risk
Although cannabis use is considered relatively benign, there is an increasing appreciation of the 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Movers & Shakers: Creo, Harvest Health & Recreation, Glass House, Flora Growth, Anebulo, Cannformatics, Republic Brands
Creo Taps Graeme Kenny To Serve As New CRO Cannabinoid ingredient company Creo has appointed Graeme Kenny as i... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Over-Intoxication Results in Millions of Visits to the ER per Year
The burden on the healthcare system from cannabis use is often underappreciated, because many see the risks of smoking marijuana as low. However, t... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Danger of Synthetic Cannabinoids
A problem of increasing social importance is the rise in the use of synthetic cannabis alternatives, commonly called K2 or Spice or a number of oth... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Underappreciated Risk Of Pediatric Cannabis Overdose
There are major risks associated with the consumption of large amounts of cannabis by young children. Unlike in adults, the risks to children 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Dark Side of Cannabis Legalization and one Biotech Company's Solution
Photo credits: Tim Foster As of July 2021, 18 states have legalized recreational marijuana while another 18 have legalized cannabis solel... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials
Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 20) Alexion Pharmaceuticals, Inc... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
48 Biggest Movers From Friday
Gainers Annovis Bio, Inc. (NASDAQ: ANVS) shares surged 127.3% to close at $60.00 on Friday after the company announced new results from a Phase 2 study evaluating its lead drug... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.